Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified FOLFOXIRI
- Development stage
- Phase 3
- Lead developer
- GONO Cooperative Group
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Modified FOLFOXIRI is a chemotherapy regimen that combines folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, and irinotecan. It is used primarily for the treatment of metastatic colorectal cancer. The "m" prefix likely indicates a modification to the standard FOLFOXIRI dosing regimen. The standard FOLFOXIRI regimen works through multiple mechanisms: fluorouracil inhibits DNA synthesis, oxaliplatin forms DNA adducts resistant to repair, and irinotecan inhibits topoisomerase I. Folinic acid is not a chemotherapy drug but enhances the efficacy of fluorouracil. The modified regimen is typically administered every 14 days (2 weeks) and may be combined with biological agents such as bevacizumab.
- Other names
- mFOLFOXIRI
02
Targets
TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on modified FOLFOXIRI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified FOLFOXIRI.